Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

RR Ramjiawan, AW Griffioen, DG Duda - Angiogenesis, 2017 - Springer
Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …

Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect

D Huang, L Sun, L Huang, Y Chen - Journal of personalized medicine, 2021 - mdpi.com
The use of nanomedicine for antitumor therapy has been extensively investigated for a long
time. Enhanced permeability and retention (EPR) effect-mediated drug delivery is currently …

Epigenetic regulation of angiogenesis in development and tumors progression: potential implications for cancer treatment

VM Aspriţoiu, I Stoica, C Bleotu… - Frontiers in cell and …, 2021 - frontiersin.org
Angiogenesis is a multi-stage process of new blood vessel development from pre-existing
vessels toward an angiogenic stimulus. The process is essential for tissue maintenance and …

The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression

I Amelio, G Melino - Trends in biochemical sciences, 2015 - cell.com
HIFs have long been associated with resistance to therapy, metastasis, and poor survival
rates in cancer patients. In parallel, although the tumor-suppressor p53 acts as the first …

Anticancer effects and mechanisms of astragaloside-IV

L Zhou, M Li, Z Chai, J Zhang, K Cao… - Oncology …, 2022 - spandidos-publications.com
Astragalus membranaceus Bunge is widely used in Traditional Chinese Medicine to treat
various cancers. Astragaloside-IV (AS-IV) is one of the major compounds isolated from A …

Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study

M Yuan, Z Zhu, W Mao, H Wang, H Qian, J Wu… - Frontiers in …, 2021 - frontiersin.org
Introduction Anlotinib (AL3818) is a novel multi-target tyrosine kinase inhibitor (TKI) targeting
vascular endothelial growth factor receptor (VEGFR) and suppressing tumor growth …

[HTML][HTML] The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas

E Sánchez-Tilló, L Pedrosa, I Vila, Y Chen, B Győrffy… - JCI insight, 2023 - ncbi.nlm.nih.gov
Despite being in the same pathway, mutations of KRAS and BRAF in colorectal carcinomas
(CRCs) determine distinct progression courses. ZEB1 induces an epithelial-to-mesenchymal …

[HTML][HTML] Biochemical hallmarks-targeting antineoplastic nanotherapeutics

J Han, H Dong, T Zhu, Q Wei, Y Wang, Y Wang, Y Lv… - Bioactive Materials, 2024 - Elsevier
Tumor microenvironments (TMEs) have received increasing attention in recent years as they
play pivotal roles in tumorigenesis, progression, metastases, and resistance to the traditional …

TAp73-induced phosphofructokinase-1 transcription promotes the Warburg effect and enhances cell proliferation

L Li, L Li, W Li, T Chen, B Zou, L Zhao, H Wang… - Nature …, 2018 - nature.com
The Warburg effect is a prominent metabolic feature associated with neoplastic diseases;
however, the underlying mechanism remains incompletely understood. TAp73, a structural …

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression

Q Wu, F Liu, M Ge, KV Laster, L Wei, R Du, M Jiang… - Oncogene, 2022 - nature.com
The low survival rate of esophageal squamous cell carcinoma patients is primarily attributed
to technical limitations and a lack of insight regarding the molecular mechanisms …